A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Cabazitaxel (Primary) ; Rhenium-188-etidronic acid
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ReCab study
- 13 Oct 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005116-28).
- 13 Oct 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
- 01 Feb 2012 New trial record